{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:22:26Z","timestamp":1783408946734,"version":"3.54.6"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10072-026-09140-y","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:25:00Z","timestamp":1780889100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cenesthopathy with tactile hallucinations induced by foslevodopa\/foscarbidopa continuous subcutaneous infusion in advanced Parkinson\u2019s disease: a case report"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-5982","authenticated-orcid":false,"given":"Kazuhiro","family":"Iwaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"9140_CR1","first-page":"224","volume":"7","author":"H Kataoka","year":"2017","unstructured":"Kataoka H, Ueno S (2017) A review of tactile hallucinations in Parkinson\u2019s disease. Neuropsychiatry (London) 7:224\u2013227","journal-title":"Neuropsychiatry (London)"},{"key":"9140_CR2","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00415-022-11545-6","volume":"270","author":"WL Toh","year":"2023","unstructured":"Toh WL, Yolland C, Gurvich C, Barnes J, Rossell SL (2023) Non-visual hallucinations in Parkinson\u2019s disease: a systematic review. J Neurol 270:2857\u20132889","journal-title":"J Neurol"},{"key":"9140_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1447-0594.2010.00585.x","volume":"10","author":"Y Fujiwara","year":"2010","unstructured":"Fujiwara Y, Suzuki H, Yasunaga M et al (2010) Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment (MoCA-J). Geriatr Gerontol Int 10:225\u2013232","journal-title":"Geriatr Gerontol Int"},{"key":"9140_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14802\/jmd.24114","volume":"17","author":"T Tezuka","year":"2024","unstructured":"Tezuka T, Nukariya T, Kizuka Y et al (2024) Potential psychosis induced by a sustained high plasma levodopa concentration due to continuous subcutaneous foslevodopa\/foscarbidopa infusion in a patient with Parkinson\u2019s disease: A case report. J Mov Disord 17:453\u2013455","journal-title":"J Mov Disord"},{"key":"9140_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.14802\/jmd.24247","volume":"18","author":"T Nukariya","year":"2025","unstructured":"Nukariya T, Tezuka T, Okusa S et al (2025) Levodopa pharmacokinetics in switching from levodopa\/carbidopa intestinal gel to continuous subcutaneous foslevodopa\/foscarbidopa infusion in a patient with Parkinson\u2019s disease: a case report. J Mov Disord 18:179\u2013181","journal-title":"J Mov Disord"},{"key":"9140_CR6","volume-title":"Clinical Practice Guideline for Parkinson\u2019s Disease 2018","author":"Japanese Society of Neurology","year":"2018","unstructured":"Japanese Society of Neurology (2018) Clinical Practice Guideline for Parkinson\u2019s Disease 2018. Igaku-Shoin, Tokyo"},{"issue":"8","key":"9140_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY et al (2018) International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33(8):1248\u20131266","journal-title":"Mov Disord"},{"key":"9140_CR8","doi-asserted-by":"publisher","first-page":"e200534","DOI":"10.1212\/CPJ.0000000000200534","volume":"15","author":"L Ge","year":"2025","unstructured":"Ge L, Kimura Y, Kakuda K et al (2025) Atypical psychosis in Parkinson disease: a retrospective study on 24-hour continuous subcutaneous infusion of foslevodopa\/foscarbidopa. Neurol Clin Pract 15:e200534","journal-title":"Neurol Clin Pract"},{"key":"9140_CR9","doi-asserted-by":"publisher","first-page":"107896","DOI":"10.1016\/j.parkreldis.2025.107896","volume":"136","author":"N Nishikawa","year":"2025","unstructured":"Nishikawa N, Hatano T, Kamiyama D et al (2025) Predictors of discontinuation in foslevodopa\/foscarbidopa therapy for Parkinson\u2019s disease. Parkinsonism Relat Disord 136:107896","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09140-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:07:09Z","timestamp":1783408029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9140"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09140-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The institutional research committee of Iwate Medical University approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient provided written informed consent for publication of this deidentified case report with accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"K. Iwaoka, R. Nozaki, and K. Takahashi (Kenta) declare no potential conflicts of interest. M. Takahashi has received funding from Sumitomo Pharma Co., Ltd., FP Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie Inc., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Eisai Co., Ltd., and EA Pharma Co., Ltd. T. Maeda has received grants and honoraria from multiple pharmaceutical companies. All conflicts are unrelated to the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"547"}}